Background/Purpose Approximately 0.7% of US adolescents identify as transgender or gender diverse (TGD). In recent years, TGD children have been presenting for treatment at increasing rates. While this population is at increased risk for mental health comorbidities, studies have demonstrated that TGD children supported in their gender identity have decreased risk. To date, few studies have described how many TGD patients are ultimately treated or the time-to-treatment (TTT) in this population. The aim of this study was to understand medication practices, TTT, and how they vary by different demographic and clinical factors. Methods Patients were identified using TGD-related …